Add
PYMX.OB to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| PYMX.OB > SEC Filings for PYMX.OB > Form 8-K on 11-Mar-2009 | All Recent SEC Filings |
11-Mar-2009
Regulation FD Disclosure, Financial Statements and Exhibits
On March 11, 2009, PolyMedix, Inc. (the "Company") issued a press release announcing Phase IA clinical data for the Company's heptagonist compound, PMX-60056. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. The information in this Report will not be deemed as an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
99.1 Press release issued March 11, 2009 by PolyMedix, Inc.
Forward-Looking Statements
The press release attached to this Current Report on Form 8-K as Exhibit 99.1 contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends", "goal", "potential," "may," "suggest," and similar expressions. Among other things, there can be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is described under the heading "Risk Factors" in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this Current Report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
|
|